A Global Perspective on Metabolic Dysfunction-Associated Steatotic Liver Disease: From Molecular Mechanisms to Therapeutic Strategy Innovation
Nutrients · 2026
DOI: 10.3390/nu18040679 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nutrients, 2026. Verfasst von Yanhao Qiu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Toxicology and Therapeutic Chemistry, School of Pharmacy and Food Science, University of Barcelona, 08028 Barcelona, Spai…. Hauptthemen laut MEDLINE: Fatty Liver, Metabolic Syndrome, Non-alcoholic Fatty Liver Disease, Metabolic Diseases. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 220 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MICIU/AEI/10.13039/501100011033 and FEDER, UE, Generalitat de Catalunya, China Scholarship Council.
Abstract (Originalsprache)
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is a prevalent global health issue driven by metabolic syndrome, with cardiovascular disease being the leading cause of mortality. This review synthesizes current knowledge on its multifactorial pathogenesis, the impact of sexual dimorphism, and key experimental models. The progression of MASLD involves interconnected pathways including dysregulated de novo lipogenesis, insulin resistance, mitochondrial dysfunction, gut dysbiosis, ferroptosis, and genetic and epigenetic predispositions. These mechanisms not only promote hepatic injury but also accelerate atherosclerosis. Notably, MASLD exhibits significant sexual dimorphism, influenced by physiological differences, sex hormones, genetic factors, and the microbiome. The study of these complex processes relies mostly on dietary-induced animal models, particularly in rats, which effectively recapitulate features of the human disease. Given the multifaceted nature of MASLD, the therapeutic focus is shifting from monotherapies to combination or dual-target strategies. To enable this transition, refinement of preclinical models is essential to better understand and target this complex disorder.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacology, Toxicology and Therapeutic Chemistry, School of Pharmacy and Food Science, University of Barcelona, 08028 Barcelona, Spain.
- Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition (CIBEROBN), Instituto de Salud Carlos III, 28029 Madrid, Spain.
- Institute of Biomedicine, University of Barcelona, 08028 Barcelona, Spain.
ORCID-Profile: Yanhao Qiu, Juan Carlos Laguna, Marta Alegret
Förderung
- MICIU/AEI/10.13039/501100011033 and FEDER, UE
- Generalitat de Catalunya
- China Scholarship Council
Zitieren
APA
Qiu, Y., Laguna, J. C., Alegret, M., & Vilà, L. (2026). A Global Perspective on Metabolic Dysfunction-Associated Steatotic Liver Disease: From Molecular Mechanisms to Therapeutic Strategy Innovation. Nutrients. https://doi.org/10.3390/nu18040679
Vancouver
Qiu Y, Laguna JC, Alegret M, Vilà L. A Global Perspective on Metabolic Dysfunction-Associated Steatotic Liver Disease: From Molecular Mechanisms to Therapeutic Strategy Innovation. Nutrients. 2026. doi:10.3390/nu18040679
BibTeX
@article{Qiu2026,
author = {Qiu, Yanhao and Laguna, Juan Carlos and Alegret, Marta and Vilà, Laia},
title = {A Global Perspective on Metabolic Dysfunction-Associated Steatotic Liver Disease: From Molecular Mechanisms to Therapeutic Strategy Innovation},
journal = {Nutrients},
year = {2026},
doi = {10.3390/nu18040679}
}
EUVIMED